（From left to right）HoneyBear Biosciences
CEO Simon Chuang,
Vice Chairwoman Sarina Lin,
Chairman Edward Wang,
A*STAR
Innovation & Enterprise,
Deputy Chief Executive, Prof. Yeo Yee Chia, and Senior Director of PharmBio Bioprocessing Industry Cluster, Ms. Neo Kah Yean etc. six people.
CEO Simon Chuang,
Vice Chairwoman Sarina Lin,
Chairman Edward Wang,
A*STAR
Innovation & Enterprise,
Deputy Chief Executive, Prof. Yeo Yee Chia, and Senior Director of PharmBio Bioprocessing Industry Cluster, Ms. Neo Kah Yean etc. six people.
Improving Cancer Treatment Outcomes with Next-Generation Antibody-Radionuclide Conjugates (ARCs)
HoneyBear Biosciences Inc. (HoneyBear), recently named ‘Best ADC Developer in Taiwan’ at the 2025 Asia Pacific Biopharma Excellence Awards (ABEA) is proud to announce that we have secured two licenses from Singapore’s Agency for Science, Technology and Research (A*STAR) to develop Antibody-Radionuclide Conjugates (ARCs) to tackle cancer. The signing ceremony to officiate these commercial licenses took place at Biopolis, Singapore on Wednesday, 12 March 2025.
The two licenses include:
By combining HoneyBear’s patented CoNectar™ technology with A*STAR’s technologies, we aim to revolutionise next-generation ARCs to a new era. This advanced approach precisely delivers radiation to tumour cells, enhancing treatment effectiveness while minimising harm to healthy tissues. As a result, patients may benefit from fewer side effects, better treatment outcomes, and an improved quality of life during cancer therapy. Together, these efforts will help develop cutting-edge therapies that address critical unmet medical needs, offering new hope to patients worldwide.
HoneyBear Biosciences Inc. (HoneyBear), recently named ‘Best ADC Developer in Taiwan’ at the 2025 Asia Pacific Biopharma Excellence Awards (ABEA) is proud to announce that we have secured two licenses from Singapore’s Agency for Science, Technology and Research (A*STAR) to develop Antibody-Radionuclide Conjugates (ARCs) to tackle cancer. The signing ceremony to officiate these commercial licenses took place at Biopolis, Singapore on Wednesday, 12 March 2025.
The two licenses include:
- An exclusive license to develop and utilise antibodies created by the A*STAR Singapore Immunology Network (A*STAR SIgN) for ARC development.
- A non-exclusive license for the multicistronic expression vector technology from the A*STAR Bioprocessing Technology Institute (A*STAR BTI), which will be utilised for the efficient production of the antibody.
By combining HoneyBear’s patented CoNectar™ technology with A*STAR’s technologies, we aim to revolutionise next-generation ARCs to a new era. This advanced approach precisely delivers radiation to tumour cells, enhancing treatment effectiveness while minimising harm to healthy tissues. As a result, patients may benefit from fewer side effects, better treatment outcomes, and an improved quality of life during cancer therapy. Together, these efforts will help develop cutting-edge therapies that address critical unmet medical needs, offering new hope to patients worldwide.
- GeneOnline：https://www.geneonline.com/singapores-astar-invests-in-honeybear-accelerating-arc-cancer-drug-development/
- Eye on TAIWAN：https://eyeontw.com/2025/03/astar-partners-with-honeybear-biosciences-to-advance-arc-cancer-therapies/
